PCOS and cancer risk.

Jakimiuk, Artur; Issat, Tadeusz

doi:10.2478/v10042-009-0092-1

Cited by 6 publications

(4 citation statements)

References 54 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, much more research needs to be done to support this. High risk of endometrial cancer as much as about 9% have been found among women with this syndrome (Dumesic & Lobo, 2013;Jakimiuk & Issat, 2010). Obesity, improper ovulation and insulin resistance have been found to be high risk factors for the occurrence of endometrial cancer among women with PCOS.…”

Section: Literature Review and Discussionmentioning

confidence: 99%

Recent Advancement in Biological Sciences

2021

View full text Add to dashboard Cite

show abstract

Section: Literature Review and Discussionmentioning

confidence: 99%

Recent Advancement in Biological Sciences

2021

View full text Add to dashboard Cite

show abstract

“…Pyruvate kinase catalyzes the last step of glycolysis where phosphoenolpyruvate is converted to ADP. PKM2 is known to interact with a variety of biological molecules such as A-Raf, FGFR-1 and Jak-2 mutant and is also implicated in cancer metabolism (39), which could contribute to the increased incidence of certain malignancies observed in T2DM and PCOS compared with the rest of the population (40,41). For this reason, it should be further explored whether the increased levels of PKM1/M2 observed in both T2DM and PCOS may represent a common defect in glucose metabolism.…”

Section: Discussionmentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome

Galazis

Afxentiou

Xenophontos

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Women with polycystic ovary syndrome (PCOS) are at increased risk of developing insulin resistance and type 2 diabetes mellitus (T2DM). In this study, we attempted to list the proteomic biomarkers of PCOS and T2DM that have been published in the literature so far. We identified eight common biomarkers that were differentially expressed in both women with PCOS and T2DM when compared with healthy controls. These include pyruvate kinase M1/M2, apolipoprotein A-I, albumin, peroxiredoxin 2, annexin A2, a-1-B-glycoprotein, flotillin-1 and haptoglobin. These biomarkers could help improve our understanding of the links between PCOS and T2DM and could be potentially used to identify subgroups of women with PCOS at increased risk of T2DM. More studies are required to further evaluate the role these biomarkers play in women with PCOS and T2DM.European Journal of Endocrinology 168 R33-R43

show abstract

“…Studies have suggested that these factors possess the capacity to directly stimulate the proliferation of cancer cells. [3] Studies have established a connection between PCOS and cancers affecting the endometrium, ovaries, kidneys, hematological system, and pancreas. Progress in comprehending the molecular processes involved in PCOS has facilitated these discoveries.…”

Section: Introductionmentioning

confidence: 99%

Identification of Key Genes Associated With Pcos (Poly Cystic Ovarian Syndrome) and Endometrial/Ovarian Cancer Through Bioinformatics

Raulo,

Qazi

2024

Preprint

View full text Add to dashboard Cite

Background: PCOS, a common endocrine disorder, is linked to increased risks of endometrial cancer (EC) and ovarian cancer (OC). Our study utilizes bioinformatics analysis to identify shared gene signatures and elucidate biological processes between EC/OC and PCOS. Materials and Methods: Gene expression profiles for PCOS (GSE199225), endometrial cancer (GSE215413), and ovarian cancer (GSE174670) were obtained from the GEO database. Hub genes were identified through functional enrichment analysis and protein-protein interaction. Drug identification analyses were employed to find drugs targeting the hub genes. Result: Key hub genes linking PCOS and EC includes RECQL4, RAD54L, ATR, CHTF18, WDHD1, CDT1, PLK1, PKMYT1, RAD18, and RPL3; for PCOS and OC, they include HMOX1, TXNRD1, NQO1, GCLC, GSTP1, PRDX1, SOD1, GPX3, BOP1, and BYSL. Gene Ontology analysis revealed DNA Metabolic Processes in PCOS and EC, while in PCOS and OC, it identified the Removal of Superoxide Radicals. KEGG Pathway analysis highlighted Cell cycle in PCOS and EC and Hepatocellular carcinoma in PCOS and OC. Potential drugs for PCOS and EC include quercetin, calcitriol, and testosterone; for PCOS and OC, eugenol and 1-chloro-2,4-dinitrobenzene are identified. Conclusion: These findings offer insights into potential therapeutic targets and pathways linking PCOS with EC and OC, enhancing our understanding of the molecular mechanisms involved in these associations.

show abstract

PCOS and cancer risk.

Cited by 6 publications

References 54 publications

Recent Advancement in Biological Sciences

Recent Advancement in Biological Sciences

MECHANISMS IN ENDOCRINOLOGY: Proteomic biomarkers of type 2 diabetes mellitus risk in women with polycystic ovary syndrome

Identification of Key Genes Associated With Pcos (Poly Cystic Ovarian Syndrome) and Endometrial/Ovarian Cancer Through Bioinformatics

Contact Info

Product

Resources

About